» Articles » PMID: 34203203

The Roles of Pseudophosphatases in Disease

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Jul 2
PMID 34203203
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The pseudophosphatases, atypical members of the protein tyrosine phosphatase family, have emerged as bona fide signaling regulators within the past two decades. Their roles as regulators have led to a renaissance of the pseudophosphatase and pseudoenyme fields, catapulting interest from a mere curiosity to intriguing and relevant proteins to investigate. Pseudophosphatases make up approximately fourteen percent of the phosphatase family, and are conserved throughout evolution. Pseudophosphatases, along with pseudokinases, are important players in physiology and pathophysiology. These atypical members of the protein tyrosine phosphatase and protein tyrosine kinase superfamily, respectively, are rendered catalytically inactive through mutations within their catalytic active signature motif and/or other important domains required for catalysis. This new interest in the pursuit of the relevant functions of these proteins has resulted in an elucidation of their roles in signaling cascades and diseases. There is a rapid accumulation of knowledge of diseases linked to their dysregulation, such as neuropathies and various cancers. This review analyzes the involvement of pseudophosphatases in diseases, highlighting the function of various role(s) of pseudophosphatases involvement in pathologies, and thus providing a platform to strongly consider them as key therapeutic drug targets.

Citing Articles

Inactive metallopeptidase homologs: the secret lives of pseudopeptidases.

Lyons P Front Mol Biosci. 2024; 11:1436917.

PMID: 39050735 PMC: 11266112. DOI: 10.3389/fmolb.2024.1436917.


The pseudoenzyme ADPRHL1 affects cardiac function by regulating the ROCK pathway.

Tian L, Guo T, Wu F, Bai R, Ai S, Wang H Stem Cell Res Ther. 2023; 14(1):309.

PMID: 37880701 PMC: 10601310. DOI: 10.1186/s13287-023-03507-0.


Protein tyrosine phosphatase non-receptor type 2 as the therapeutic target of atherosclerotic diseases: past, present and future.

Tang X, Cheng Y, Tang C Front Pharmacol. 2023; 14:1219690.

PMID: 37670950 PMC: 10475599. DOI: 10.3389/fphar.2023.1219690.


The DUSP domain of pseudophosphatase MK-STYX interacts with G3BP1 to decrease stress granules.

Smailys J, Jiang F, Prioleau T, Kelley K, Mitchell O, Nour S Arch Biochem Biophys. 2023; 744:109702.

PMID: 37516290 PMC: 10500436. DOI: 10.1016/j.abb.2023.109702.


Emerging functions of pseudoenzymes.

Goldberg T, Sreelatha A Biochem J. 2023; 480(10):715-728.

PMID: 37204401 PMC: 10211241. DOI: 10.1042/BCJ20220373.


References
1.
Buchanan N, Zhao J, Zhu K, Patwa T, Miller F, Lubman D . Differential expression of acidic proteins with progression in the MCF10 model of human breast disease. Int J Oncol. 2007; 31(4):941-9. View

2.
Wu J, Jiang N, Lin J, Liu X . STYXL1 promotes malignant progression of hepatocellular carcinoma via downregulating CELF2 through the PI3K/Akt pathway. Eur Rev Med Pharmacol Sci. 2020; 24(6):2977-2985. DOI: 10.26355/eurrev_202003_20662. View

3.
Peti W, Page R . Molecular basis of MAP kinase regulation. Protein Sci. 2013; 22(12):1698-710. PMC: 3843625. DOI: 10.1002/pro.2374. View

4.
Wishart M, Dixon J . Gathering STYX: phosphatase-like form predicts functions for unique protein-interaction domains. Trends Biochem Sci. 1998; 23(8):301-6. DOI: 10.1016/s0968-0004(98)01241-9. View

5.
Kozlov G, Funato Y, Chen Y, Zhang Z, Illes K, Miki H . PRL3 pseudophosphatase activity is necessary and sufficient to promote metastatic growth. J Biol Chem. 2020; 295(33):11682-11692. PMC: 7450121. DOI: 10.1074/jbc.RA120.014464. View